NASDAQ:NXTC NextCure Q3 2026 Earnings Results & Report $5.98 -0.29 (-4.63%) Closing price 04:00 PM EasternExtended Trading$5.70 -0.28 (-4.67%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NextCure missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$1.29 versus the -$0.90 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call4:00 PM ET NextCure EPS ResultsActual EPS-$1.29Consensus EPS -$0.90Beat/MissMissed by -$0.39One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNextCure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NextCure Q3 2026 Earnings FAQ Did NextCure beat earnings estimates for Q3 2026? NextCure (NASDAQ:NXTC) reported earnings of -$1.29 per share for Q3 2026, missing the consensus estimate of -$0.90. The report was announced on Tuesday, November 10, 2026. NextCure Earnings HeadlinesNextCure Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 10 at 4:05 PM | globenewswire.comNextCure (NXTC) Expected to Post Quarterly Earnings on MondayNovember 1, 2026 | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)NextCure CMO Departs Amid Pending Avere MergerOctober 30, 2026 | tipranks.comNextCure Faces Court Review of Reverse Stock SplitSeptember 28, 2026 | theglobeandmail.comNextCure Ends Beltsville Lease to Cut Operating CostsSeptember 3, 2026 | tipranks.comSee More NextCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email. Email Address About NextCureNextCure (NASDAQ:NXTC) (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses. Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations. Michael Richman has served as the company’s chief executive officer and has been involved in its development as a biotechnology business.View NextCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
